Challenging historical perspectives of the 24-h chemotherapy day: Flexible chemotherapy dose-timing guidelines

Grants

Funding Acknowledgements

Peter MacCallum Cancer Centre gratefully acknowledges Roche Products, Pty Limited (Australia) for providing the funding to undertake this project. The authors would like to acknowledge the medical, pharmacy and nursing staff from the Hematology and Sarcoma units at Peter MacCallum Cancer Centre who contributed to the project steering committee and assisted with the development and implementation of the flexible dose-timing guidelines.